// App-Quantinova.ai

: New portable nasal nitric oxide (nNO) analyser differentiates primary ciliary dyskinesia (PCD) from healthy individuals

Researchers

Presenter

  • Jane Lucas

Principal Investigators

  • Margaret Leigh

  • Nicole Beydon

  • Thomas Ferkol

  • Kim Nielsen

  • Claudius Werner

  • Steven Strausbaugh

  • Stephanie Davis

  • Cros Nt

  • Ali Kermani

  • Ulla Seppala

  • Margot Macdonald-Berko

  • Kathleen Rickard

Medical Centers

  • Haematology, University Hospital Southampton, Southampton, United Kingdom

  • University of North Carolina School of Medicine, Chapel Hill, NC, United States of America

  • Hopital Enfants Armand Trousseau, Paris, France

  • St Louis Children’s Hospital, St Louis,MO, United States of America

  • Danish PCD & chILD Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

  • Universitatsklinikum Munster, Munster, Germany

  • Riley Hospital for Children, Indiana,IN, United States of America

  • CROS NT, Chapel Hill,NC, United States of America

  • Circassia AB, Solna, Sweden

  • Circassia Pharmaceuticals, Morrisville, NC, United States,

Locations

  • United Kingdom

  • United States

  • France

  • Denmark

  • Germany

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Pulmonary/Respiratory Diseases

Disease

  • Primary ciliary dyskinesia

Biomarkers

  • N/A

Drug/Treatment

  • Nitric oxide

Outcome

  • N/A

Study Design

  • Randomized

  • Non Randomized

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved